Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 251

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

Open access
Connors, Jean M., Brooks, Maria M., Sciurba, Frank C., Krishnan, Jerry A., Bledsoe, Joseph R., Kindzelski, Andrei, Baucom, Amanda L., Kirwan, Bridget-Anne, Eng, Heather, Martin, Deborah, Zaharris, Elaine, Everett, Brendan, Castro, Lauren, Shapiro, Nancy L., Lin, Janet Y., Hou, Peter C., Pepine, Carl J., Handberg, Eileen, Haight, Daniel O., Wilson, Jason W., Majercik, Sarah, Fu, Zhuxuan, Zhong, Yongqi, Venugopal, Vidya, Beach, Scott, Wisniewski, Steve, Ridker, Paul M, ACTIV-4B Investigators, Brakenridge, Scott, Leifer, Eric, Troxel, Andrea, Maggioni, Aldo, Jacobson, Jeff, Lopes, Renato D., Mentz, Rob, Sholzberg, Michelle, Alexander, John H., Schreiber, Donald, Yadav, Kabir, Vecchiarelli, Anthony, Oguchi, Godson, Merck, Lisa, Altagracia, Victoria, Gonzalez, Antonio, Angiolillo, Dominick, Blind, Fred, Cienki, John, Loy, Reinaldo, Armas, Eddie, Martinez, Juvenal, Ruiz Unger, Juan, Gulati, Vishal, Robinson, Temple, Kroker-Bode, Claudia, Wilson, Jason, Beiser, David, Hagan, Maggie, Cohen, Jonathan, Goonewardena, Sascha, Fletcher, Jeffrey, Dolor, Rowena, Jarrett, Thomas, Patel, Vijay, Wang, Ming-Li, Acquisto, Nicole, Mehrle, Anderson, Saangeeta, Khetpal, Hanna, Nicholas, Abouhouli, Hassan, Weissman, Alexandra, Purighalla, Raman, Bennett, Nathan, Jay, Gregory, Barbham, David, Milling, TJ, Abdelsayed, Dalla, McPherson, David, Salvato, Patricia, Orgwu, Chukwumeka, Mundluru, Anuradha, Olusola, Patti, Majercik, Sarah, Lewis, William · 2021 · JAMA

Abstract

Importance: Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy, although the risks and benefits of this intervention among outpatients with COVID-19 have not been established. Objective: To assess whether anticoagulant or antiplatelet therapy can safely reduce major adverse cardiopulmonary outcomes among symptomatic but clinically stable outpatients with COVID-19. Design, Setting, and Participants: The ACTIV-4B Outpatient Thrombosis Prevention Trial was designed as a minimal-contact, adaptive, randomized, double-blind, placebo-controlled trial to compare anticoagulant and antiplatelet therapy among 7000 symptomatic but clinically stable outpatients with COVID-19. The trial was conducted at 52 US sites between September 2020 and June 2021; final follow-up was August 5, 2021. Prior to initiating treatment, participants were required to have platelet count greater than 100 000/mm3 and estimated glomerular filtration rate greater than 30 mL/min/1.73 m2. Interventions: Random allocation in a 1:1:1:1 ratio to aspirin (81 mg orally once daily; n = 164), prophylactic-dose apixaban (2.5 mg orally twice daily; n = 165), therapeutic-dose apixaban (5 mg orally twice daily; n = 164), or placebo (n = 164) for 45 days. Main Outcomes and Measures: The primary end point was a composite of all-cause mortality, symptomatic venous or arterial thromboembolism, myocardial infarction, stroke, or hospitalization for cardiovascular or pulmonary cause. The primary analyses for efficacy and bleeding events were limited to participants who took at least 1 dose of trial medication. Results: On June 18, 2021, the trial data and safety monitoring board recommended early termination because of lower than anticipated event rates; at that time, 657 symptomatic outpatients with COVID-19 had been randomized (median age, 54 years [IQR, 46-59]; 59% women). The median times from diagnosis to randomization and from randomization to initiation of study treatment were 7 days and 3 days, respectively. Twenty-two randomized participants (3.3%) were hospitalized for COVID-19 prior to initiating treatment. Among the 558 patients who initiated treatment, the adjudicated primary composite end point occurred in 1 patient (0.7%) in the aspirin group, 1 patient (0.7%) in the 2.5-mg apixaban group, 2 patients (1.4%) in the 5-mg apixaban group, and 1 patient (0.7%) in the placebo group. The risk differences compared with placebo for the primary end point were 0.0% (95% CI not calculable) in the aspirin group, 0.7% (95% CI, -2.1% to 4.1%) in the 2.5-mg apixaban group, and 1.4% (95% CI, -1.5% to 5.0%) in the 5-mg apixaban group. Risk differences compared with placebo for bleeding events were 2.0% (95% CI, -2.7% to 6.8%), 4.5% (95% CI, -0.7% to 10.2%), and 6.9% (95% CI, 1.4% to 12.9%) among participants who initiated therapy in the aspirin, prophylactic apixaban, and therapeutic apixaban groups, respectively, although none were major. Findings inclusive of all randomized patients were similar. Conclusions and Relevance: Among symptomatic clinically stable outpatients with COVID-19, treatment with aspirin or apixaban compared with placebo did not reduce the rate of a composite clinical outcome. However, the study was terminated after enrollment of 9% of participants because of an event rate lower than anticipated. Trial Registration: ClinicalTrials.gov Identifier: NCT04498273.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2021.17272

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 251

Metadata

Authors
Connors, J. M., Brooks, M. M., Sciurba, F. C., Krishnan, J. A., Bledsoe, J. R., Kindzelski, A., Baucom, A. L., Kirwan, B.-A., Eng, H., Martin, D., Zaharris, E., Everett, B., Castro, L., Shapiro, N. L., Lin, J. Y., Hou, P. C., Pepine, C. J., Handberg, E., Haight, D. O., Wilson, J. W., Majercik, S., Fu, Z., Zhong, Y., Venugopal, V., Beach, S., Wisniewski, S., Ridker, P. M., ACTIV-4B Investigators, Brakenridge, S., Leifer, E., Troxel, A., Maggioni, A., Jacobson, J., Lopes, R. D., Mentz, R., Sholzberg, M., Alexander, J. H., Schreiber, D., Yadav, K., Vecchiarelli, A., Oguchi, G., Merck, L., Altagracia, V., Gonzalez, A., Angiolillo, D., Blind, F., Cienki, J., Loy, R., Armas, E., Martinez, J., Ruiz Unger, J., Gulati, V., Robinson, T., Kroker-Bode, C., Wilson, J., Beiser, D., Hagan, M., Cohen, J., Goonewardena, S., Fletcher, J., Dolor, R., Jarrett, T., Patel, V., Wang, M.-L., Acquisto, N., Mehrle, A., Saangeeta, K., Hanna, N., Abouhouli, H., Weissman, A., Purighalla, R., Bennett, N., Jay, G., Barbham, D., Milling, T., Abdelsayed, D., McPherson, D., Salvato, P., Orgwu, C., Mundluru, A., Olusola, P., Majercik, S., & Lewis, W.
Venue
JAMA
Published
2021-11-02
Volume
326
Issue
17
Pages
1703
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W3206483794
Cited by
251
References
8
FWCI
16.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2021.17272
The paper
Connors, J. M., Brooks, M. M., Sciurba, F. C., Krishnan, J. A., Bledsoe, J. R., Kindzelski, A., Baucom, A. L., Kirwan, B.-A., Eng, H., Martin, D., Zaharris, E., Everett, B., Castro, L., Shapiro, N. L., Lin, J. Y., Hou, P. C., Pepine, C. J., Handberg, E., Haight, D. O., . . . Lewis, W. (2021). Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2021.17272

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.